Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Ratios

Catalyst Pharmaceuticals (CPRX) Other financing activities (2024)

Catalyst Pharmaceuticals filings provide 1 years of Other financing activities readings, the most recent being $296000.0 for Q1 2024.

On a quarterly basis, Other financing activities changed N/A to $296000.0 in Q1 2024 year-over-year; TTM through Dec 2024 was $296000.0, a N/A change, with the full-year FY2024 number at $296000.0, changed N/A from a year prior.
Other financing activities hit $296000.0 in Q1 2024 for Catalyst Pharmaceuticals.
In the past five years, Other financing activities ranged from a high of $296000.0 in Q1 2024 to a low of $296000.0 in Q1 2024.